Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer

IF 2.7 3区医学 Q2 ONCOLOGY

Clinical breast cancer Pub Date : 2026-05-01 Epub Date: 2026-03-18 DOI:10.1016/j.clbc.2026.03.010

Kyoo Hyun Kim , Joohyuk Sohn , Min Hwan Kim , Jee Hung Kim , Jee Hyun Ahn , Jee Ye Kim , Hyung Seok Park , Seho Park , Seung-Il Kim , Joon Jeong , Gun Min Kim

{"title":"Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer","authors":"Kyoo Hyun Kim , Joohyuk Sohn , Min Hwan Kim , Jee Hung Kim , Jee Hyun Ahn , Jee Ye Kim , Hyung Seok Park , Seho Park , Seung-Il Kim , Joon Jeong , Gun Min Kim","doi":"10.1016/j.clbc.2026.03.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite advancements in breast cancer treatments, brain metastases (BM) remain a major clinical challenge in metastatic breast cancer (MBC), adversely affecting survival and quality of life. This study investigates the lifetime incidence, temporal trends, and survival outcomes of BM across different breast cancer subtypes in patients with MBC.</div></div><div><h3>Patients and Methods</h3><div>We retrospectively analyzed a database of 2311 MBC patients treated between 2005 and 2024 at Yonsei Cancer Center and Gangnam Severance Hospital in Korea. Clinical, radiologic, and molecular data were extracted from the institutional database. BM incidence rates were compared across subtypes. Survival outcomes were analyzed based on BM burden and local treatment strategies.</div></div><div><h3>Results</h3><div>BM developed in 22.7% (525/2311) of MBC patients throughout the disease course. The incidence was highest in HER2-positive(+) (34.2%) and triple-negative breast cancer (TNBC) (33.0%) subtypes, while significantly lower in HR+/HER2− breast cancer (14.4%). The annual incidence of BM showed an early peak pattern, with 94.7% of TNBC cases and 82.2% of HER2+ cases occurring within the first 3 years of metastatic disease. In contrast, HR+/HER2− cases showed no distinct peak pattern over time. Survival outcomes were closely linked to tumor burden, including the number of BM lesions (<em>P</em> <em><</em> .0001) and the presence of symptoms (<em>P</em> <em>=</em> .021).</div></div><div><h3>Conclusion</h3><div>This study highlights the high risk of early BM in HER2+ and TNBC subtypes, with most cases occurring within the first 3 years of metastatic disease. These findings support the need for early surveillance strategies in these high-risk groups to enable timely detection and intervention.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 5","pages":"Pages 121-129.e4"},"PeriodicalIF":2.7000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S152682092600042X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Despite advancements in breast cancer treatments, brain metastases (BM) remain a major clinical challenge in metastatic breast cancer (MBC), adversely affecting survival and quality of life. This study investigates the lifetime incidence, temporal trends, and survival outcomes of BM across different breast cancer subtypes in patients with MBC.

Patients and Methods

We retrospectively analyzed a database of 2311 MBC patients treated between 2005 and 2024 at Yonsei Cancer Center and Gangnam Severance Hospital in Korea. Clinical, radiologic, and molecular data were extracted from the institutional database. BM incidence rates were compared across subtypes. Survival outcomes were analyzed based on BM burden and local treatment strategies.

Results

BM developed in 22.7% (525/2311) of MBC patients throughout the disease course. The incidence was highest in HER2-positive(+) (34.2%) and triple-negative breast cancer (TNBC) (33.0%) subtypes, while significantly lower in HR+/HER2− breast cancer (14.4%). The annual incidence of BM showed an early peak pattern, with 94.7% of TNBC cases and 82.2% of HER2+ cases occurring within the first 3 years of metastatic disease. In contrast, HR+/HER2− cases showed no distinct peak pattern over time. Survival outcomes were closely linked to tumor burden, including the number of BM lesions (P < .0001) and the presence of symptoms (P = .021).

Conclusion

This study highlights the high risk of early BM in HER2+ and TNBC subtypes, with most cases occurring within the first 3 years of metastatic disease. These findings support the need for early surveillance strategies in these high-risk groups to enable timely detection and intervention.

查看原文本刊更多论文

转移性乳腺癌脑转移的亚型特异性风险和时间动态。

背景：尽管乳腺癌治疗取得了进展，但脑转移（BM）仍然是转移性乳腺癌（MBC）的主要临床挑战，对生存和生活质量产生不利影响。本研究调查了不同乳腺癌亚型MBC患者乳腺癌的终生发病率、时间趋势和生存结果。患者和方法：我们回顾性分析了2005年至2024年间在韩国延世癌症中心和江南Severance医院接受治疗的2311例MBC患者的数据库。临床、放射学和分子数据从机构数据库中提取。比较不同亚型间脑脊膜炎的发病率。生存结果根据脑转移负担和局部治疗策略进行分析。结果：22.7%（525/2311）的MBC患者在整个病程中发生脑转移。在HER2阳性（+）亚型和三阴性乳腺癌（TNBC）亚型中发病率最高（34.2%），而在HR+/HER2-亚型中发病率明显较低（14.4%）。BM的年发病率呈现早期高峰模式，94.7%的TNBC病例和82.2%的HER2+病例发生在转移性疾病的前3年内。相比之下，HR+/HER2-病例没有明显的峰值模式。生存结果与肿瘤负荷密切相关，包括BM病变数量（P< 0.0001）和症状的存在（P= 0.021）。结论：该研究强调了HER2+和TNBC亚型早期BM的高风险，大多数病例发生在转移性疾病的前3年内。这些发现支持需要在这些高危人群中采取早期监测战略，以便及时发现和干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.